A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT04760314 · COMPLETED

Trial details

NCT number: NCT04760314
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic

Start date: 2021-03-10
Primary completion: 2022-07-31
Enrollment: 286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.